Zolbetuximab: research progress and prospects in the treatment of gastric and gastroesophageal junction cancer targeting claudin 18.2
Recenti Progressi in Medicina · 01.05.2026 · 117 (5)
DOI: 10.1701/4698.47106 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Recenti Progressi in Medicina, erschienen am 01.05.2026. Verfasst von Shu-Wei Qian und 2 weiteren Autor:innen. Beteiligte Einrichtung: Chengdu University of TCM, Clinical Research Center for Traditional Chinese Medicine Cardiovascular Disease, Chengdu, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Esophageal Neoplasms, Antibodies, Monoclonal, Humanized, Claudins.
Abstract (Originalsprache)
Gastric cancer (GC) and esophagogastric junction cancer (EGJC) impose a severe global burden, with traditional treatments plagued by poor efficacy, high toxicity, and chemoresistance. Claudin 18.2 (CLDN18.2), a highly tissue-specific target, is abnormally overexpressed in GC/EGJC with limited overlap with HER2 positivity or PD-L1 CPS ≥5, making it ideal for precision therapy. Zolbetuximab, a CLDN18.2-targeted ADC, exerts anti-tumor effects via “targeted binding-endocytosis-MMAE release”, reducing systemic toxicity versus traditional chemotherapy. Pivotal trials (MONO, FAST, SPOTLIGHT/GLOW, ILUSTRO) confirmed its monotherapy efficacy and superior PFS/OS when combined with chemotherapy (EOX, mFOLFOX6, CAPOX) in CLDN18.2-positive (≥70% staining), HER2-negative advanced GC/EGJC patients, with manageable safety. SPOTLIGHT/GLOW laid the foundation for its first-line approval. Post-approval, it may expand to other CLDN18.2-positive tumors and neoadjuvant/adjuvant therapy, with combination regimen optimization. However, MMAE’s long-term cumulative toxicity, uncertain safety in special populations, and rare severe adverse reactions require real-world validation. This review systematically summarizes zolbetuximab’s research progress, providing a reference for clinical application and future studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Chengdu University of TCM, Clinical Research Center for Traditional Chinese Medicine Cardiovascular Disease, Chengdu, China.
- Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Zitieren
APA
Qian, S. W., Xiong, J. H., & Leng, J. C. (2026). Zolbetuximab: research progress and prospects in the treatment of gastric and gastroesophageal junction cancer targeting claudin 18.2. Recenti Progressi in Medicina, 117(5). https://doi.org/10.1701/4698.47106
Vancouver
Qian SW, Xiong JH, Leng JC. Zolbetuximab: research progress and prospects in the treatment of gastric and gastroesophageal junction cancer targeting claudin 18.2. Recenti Progressi in Medicina. 2026;117(5). doi:10.1701/4698.47106
BibTeX
@article{Qian2026,
author = {Qian, Shu-Wei and Xiong, Jun-Hao and Leng, Jian-Chun},
title = {Zolbetuximab: research progress and prospects in the treatment of gastric and gastroesophageal junction cancer targeting claudin 18.2},
journal = {Recenti Progressi in Medicina},
year = {2026},
volume = {117},
number = {5},
doi = {10.1701/4698.47106}
}
EUVIMED